Fractyl Health (GUTS) Total Current Liabilities (2023 - 2026)
Fractyl Health's (GUTS) quarterly Total Current Liabilities came in at $15.4 million in Q1 2026, down 18.05% YoY from $18.8 million in Q1 2025, and down 15.94% on a QoQ basis from $18.3 million in Q4 2025.
Fractyl Health (GUTS) Total Current Liabilities (2023 - 2026) Analysis & Trends
Fractyl Health (GUTS) has 4 years of Total Current Liabilities data on file, last reported at $15.4 million in Q1 2026.
- Quarterly Total Current Liabilities fell 18.05% year-over-year to $15.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.4 million (down 18.05% YoY) and the FY2025 annual result came in at $18.3 million, down 7.31% from the prior year.
- Total Current Liabilities eased to $15.4 million in Q1 2026, from $18.3 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $21.8 million in Q2 2025 to a low of $11.2 million in Q4 2023.
- A 4-year average of $16.7 million and a median of $17.0 million in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Current Liabilities jumped 76.75% — and 2026, when it decreased 18.05%.
- Tracing GUTS's Total Current Liabilities over 4 years: stood at $11.2 million in 2023, then jumped by 76.75% to $19.8 million in 2024, then fell by 7.31% to $18.3 million in 2025, then dropped by 15.94% to $15.4 million in 2026.
- The last three Total Current Liabilities figures came in at $15.4 million (Q1 2026), $18.3 million (Q4 2025), and $18.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Fractyl Health | 109.12 Mn | 109.12 Mn | - | 15.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.74 Mn |
| Mar 31, 2026 | 15.41 Mn |
| Dec 31, 2025 | 18.33 Mn |
| Sep 30, 2025 | 18.68 Mn |
| Jun 30, 2025 | 21.83 Mn |
| Mar 31, 2025 | 18.80 Mn |
| Dec 31, 2024 | 19.78 Mn |
| Sep 30, 2024 | 15.72 Mn |
| Jun 30, 2024 | 14.28 Mn |
| Mar 31, 2024 | 13.27 Mn |
| Dec 31, 2023 | 11.19 Mn |